The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 11, 2023

Filed:

Mar. 25, 2020
Applicant:

Acceleron Pharma Inc., Cambridge, MA (US);

Inventors:

Ravindra Kumar, Acton, MA (US);

John Knopf, Carlisle, MA (US);

Assignee:

ACCELERON PHARMA INC., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/18 (2006.01); A61P 11/00 (2006.01); A61K 38/17 (2006.01); A61P 7/00 (2006.01); A61K 45/06 (2006.01); A61K 38/45 (2006.01); C07K 14/71 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1875 (2013.01); A61K 38/179 (2013.01); A61K 38/1796 (2013.01); A61K 38/45 (2013.01); A61K 45/06 (2013.01); A61P 7/00 (2018.01); A61P 11/00 (2018.01); C07K 14/71 (2013.01); C07K 2319/30 (2013.01);
Abstract

In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.


Find Patent Forward Citations

Loading…